Deutsch English Français

Contact

EP4499225

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP4499225

EP4499225 - PHIALOMUSTIN B (1) FOR TREATMENT OF PARKINSON'S DISEASE (PD) AND AMYOTROPHIC LATERAL SCLEROSIS (ALS) [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 03.01.2025 Database last updated on 11.04.2026
Former	The international publication has been made Status updated on 07.10.2023
Most recent event Tooltip	26.03.2026	New entry: Renewal fee paid
Applicant(s)	For all designated states Council of Scientific and Industrial Research an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) Anusandhan Bhawan, 2 Rafi Marg New Delhi, Delhi 110 001 / IN
	For all designated states National Institute of Mental Health and Neurosciences (NIMHANS) Hosur Road, Karnataka Bangalore 560029 / IN
	[N/P]
Former [2025/06]	For all designated states Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860 Anusandhan Bhawan, 2 Rafi Marg New Delhi, Delhi 110 001 / IN
	For all designated states National Institute of Mental Health and Neurosciences (NIMHANS) Hosur Road, Karnataka Bangalore 560029 / IN
Inventor(s)	01 / B., Padmanabhan Karnataka Bangalore 560029 / IN
	02 / ASIF, Ali Delhi 110007 / IN
	03 / DESHMUKH, Prashant Karnataka Bangalore 560029 / IN
	04 / UNNI, Sruthi Karnataka Bangalore 560029 / IN
	05 / YEDUKONDALU, Nalli Jammu / IN
	06 / M M, Srinivas Bharath Karnataka Bangalore 560029 / IN
	07 / RIYAZ-UL-HASSAN, Syed Jammu / IN
	08 / AHMED, Wani Zahoor Jammu / IN
	[2025/06]
Representative(s)	Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL
	[2025/06]
Application number, filing date	23778704.9	30.03.2023
	[2025/06]
	WO2023IN50315
Priority number, date	IN202211019288	30.03.2022 Original published format: IN202211019288
	[2025/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2023187838
	Date:	05.10.2023
	Language:	EN
	[2023/40]
	Type:	A1 Application with search report
	No.:	EP4499225
	Date:	05.02.2025
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.10.2023 takes the place of the publication of the European patent application.
	[2025/06]
Search report(s)	International search report - published on:	IN	05.10.2023
	(Supplementary) European search report - dispatched on:	EP	20.02.2026
Classification	IPC:	A61K31/201, A61P25/16, A61P25/28, A61K35/17	[2026/13]
	CPC:	A61P25/16 (EP); A61K31/201 (EP); A61P25/28 (EP); A61K36/06 (EP); A61K36/88 (EP)
	Former IPC [2025/06]	A61P25/16, A61P25/28, A61K35/17
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/06]
Title	German:	PHIALOMUSTIN B(1) ZUR BEHANDLUNG VON MORBUS PARKINSON UND AMYOTROPHER LATERALSKLEROSE (ALS)	[2025/06]
	English:	PHIALOMUSTIN B (1) FOR TREATMENT OF PARKINSON'S DISEASE (PD) AND AMYOTROPHIC LATERAL SCLEROSIS (ALS)	[2025/06]
	French:	PHIALOMUSTINE B (1) PERMETTANT LE TRAITEMENT DE LA MALADIE DE PARKINSON (PD) ET DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA)	[2025/06]
Entry into regional phase	27.06.2024	National basic fee paid
	27.06.2024	Search fee paid
	27.06.2024	Designation fee(s) paid
	27.06.2024	Examination fee paid
Examination procedure	27.06.2024	Examination requested [2025/06]
	02.04.2025	Amendment by applicant (claims and/or description)
Fees paid	Renewal fee
	25.03.2025	Renewal fee patent year 03
	25.03.2026	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[IX] NALLI YEDUKONDALU ET AL: "Phialomustin A-D, new antimicrobial and cytotoxic metabolites from an endophytic fungus, Phialophora mustea", RSC ADVANCES, vol. 5, no. 115, 1 January 2015 (2015-01-01), pages 95307 - 95312, XP093098362, DOI: 10.1039/C5RA18121F [I] 9 * abstract * * compound 2 * * figures 1,2 * [X] 1-2,4-8 DOI: http://dx.doi.org/10.1039/C5RA18121F
		[A] BARBER S C ET AL: "Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target", FREE RADICAL BIOLOGY & MEDICINE, ELSEVIER INC, US, vol. 48, no. 5, 1 March 2010 (2010-03-01), pages 629 - 641, XP026878487, ISSN: 0891-5849, [retrieved on 20091204] [A] 1-15 * abstract * * page 632, column l, paragraph 2 * * page 635, column l, paragraph 5 - page 636, column r, paragraph 3 * * figures 2-4 *
		[A] NIU YINGCAI ET AL: "Nrf2 as a potential target for Parkinson's disease therapy", JOURNAL OF MOLECULAR MEDICINE, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 99, no. 7, 12 April 2021 (2021-04-12), pages 917 - 931, XP037496205, ISSN: 0946-2716, [retrieved on 20210412], DOI: 10.1007/S00109-021-02071-5 [A] 1-15 * abstract * * page 918, column l, paragraph 3 - page 919, column r, paragraph 1 * * page 924, column r, paragraph 2 - page 927, column l, paragraph 1 * * figure 2 * * table 1 * DOI: http://dx.doi.org/10.1007/s00109-021-02071-5
	International search	[A] WO2019157440 (DARTMOUTH COLLEGE et al.) [A] 1-11 * Claims: 50, 52, 66, 94 and 118 *
		[A] NALLI YEDUKONDALU, MIRZA DANIA N., WANI ZAHOOR A., WADHWA BHUMIKA, MALLIK FAYAZ A., RAINA CHAND, CHAUBEY ASHA, RIYAZ-UL-HASSAN SYE: "Phialomustin AD, new antimicrobial and cytotoxic metabolites from an endophytic fungus, Phialophora mustea", RSC ADVANCES, vol. 5, no. 115, 1 January 2015 (2015-01-01), pages 95307 - 95312, XP093098362, DOI: 10.1039/C5RA18121F [A] 1-11 DOI: http://dx.doi.org/10.1039/C5RA18121F

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.